Optional copayments on anti-cancer drugs.
Centre for Health Economics, Mario Negri Institute for Pharmacological Research, 24020 Ranica, BG, Italy.
Katelijne
K
van de Vooren
Alessandro
A
Curto
Livio
L
Garattini
D000911:Antibodies, Monoclonal / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics; D000970:Antineoplastic Agents / Q000191:economics*; D000068258:Bevacizumab; D000068818:Cetuximab; D003363:Cost Control; D003362:Cost-Benefit Analysis; D003669:Deductibles and Coinsurance; D017048:Health Care Costs; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000191:economics*; D010358:Patient Participation
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000068818:Cetuximab